Inverness carries on along acquisition trail
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations has entered an acquisition agreement with protein-based diagnostics specialist Matritech that will see it clinch its sixth purchase of the year. The Matritech buy, expected to close in the fourth quarter of 2007, will cost Inverness $36m in common stock, possibly highlighting that such prolific purchases have taken their toll on the company's financial reserves.